Applications of SARS-CoV-2 serological testing: impact of test performance, sample matrices, and patient characteristics

被引:4
作者
Fung, Chun Yiu Jordan [1 ,2 ]
Scott, Mackenzie [1 ,2 ,3 ]
Lerner-Ellis, Jordan [1 ,2 ,3 ]
Taher, Jennifer [2 ,3 ,4 ]
机构
[1] Sinai Hlth, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[2] Sinai Hlth, Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[4] Sinai Hlth, Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada
关键词
SARS-CoV-2; COVID-19; serology; immunity; antibody; INTERNATIONAL STANDARD; COVID-19; ANTIBODY; INFECTION; KINETICS;
D O I
10.1080/10408363.2023.2254390
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Laboratory testing has been a key tool in managing the SARS-CoV-2 global pandemic. While rapid antigen and PCR testing has proven useful for diagnosing acute SARS-CoV-2 infections, additional testing methods are required to understand the long-term impact of SARS-CoV-2 infections on immune response. Serological testing, a well-documented laboratory practice, measures the presence of antibodies in a sample to uncover information about host immunity. Although proposed applications of serological testing for clinical use have previously been limited, current research into SARS-CoV-2 has shown growing utility for serological methods in these settings. To name a few, serological testing has been used to identify patients with past infections and long-term active disease and to monitor vaccine efficacy. Test utility and result interpretation, however, are often complicated by factors that include poor test sensitivity early in infection, lack of immune response in some individuals, overlying infection and vaccination responses, lack of standardization of antibody titers/levels between instruments, unknown titers that confer immune protection, and large between-individual biological variation following infection or vaccination. Thus, the three major components of this review will examine (1) factors that affect serological test utility: test performance, testing matrices, seroprevalence concerns and viral variants, (2) patient factors that affect serological response: timing of sampling, age, sex, body mass index, immunosuppression and vaccination, and (3) informative applications of serological testing: identifying past infection, immune surveillance to guide health practices, and examination of protective immunity. SARS-CoV-2 serological testing should be beneficial for clinical care if it is implemented appropriately. However, as with other laboratory developed tests, use of SARS-CoV-2 serology as a testing modality warrants careful consideration of testing limitations and evaluation of its clinical utility.
引用
收藏
页码:70 / 88
页数:19
相关论文
共 184 条
  • [11] [Anonymous], 2022, NIH COVID 19 TREATM
  • [12] [Anonymous], 2020, POSTCOVID COND INF H
  • [13] [Anonymous], 2023, PREN SER
  • [14] [Anonymous], 2022, CONS US ANT TESTS SA
  • [15] Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes
    Arnold, Cosby G.
    Libby, Anne
    Vest, Alexis
    Hopkinson, Andrew
    Monte, Andrew A.
    [J]. BIOLOGY OF SEX DIFFERENCES, 2022, 13 (01)
  • [16] Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study
    Augustin, Max
    Schommers, Philipp
    Stecher, Melanie
    Dewald, Felix
    Gieselmann, Lutz
    Gruell, Henning
    Horn, Carola
    Vanshylla, Kanika
    Di Cristanziano, Veronica
    Osebold, Luise
    Roventa, Maria
    Riaz, Toqeer
    Tschernoster, Nikolai
    Altmueller, Janine
    Rose, Leonard
    Salomon, Susanne
    Priesner, Vanessa
    Luers, Jan Christoffer
    Albus, Christian
    Rosenkranz, Stephan
    Gathof, Birgit
    Faetkenheuer, Gerd
    Hallek, Michael
    Klein, Florian
    Suarez, Isabelle
    Lehmann, Clara
    [J]. LANCET REGIONAL HEALTH-EUROPE, 2021, 6
  • [17] Australian Government Department of Health and Aged Care, 2020, AUSTR NAT DIS SURV P
  • [18] Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection
    Azak, Emel
    Karadenizli, Aynur
    Uzuner, Huseyin
    Karakaya, Nihan
    Canturk, Nuh Zafer
    Hulagu, Sadettin
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 113 : 58 - 64
  • [19] Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology
    Bailey, Dana
    Konforte, Danijela
    Barakauskas, Vilte E.
    Yip, Paul M.
    Kulasingam, Vathany
    Abou El Hassan, Mohamed
    Beach, Lori A.
    Blasutig, Ivan M.
    Catomeris, Peter
    Dooley, Kent C.
    Gong, Yanping
    Kavsak, Peter
    Randell, Edward W.
    Robinson, Jason L.
    Shaw, Julie
    Taher, Jennifer
    White-Al Habeeb, Nicole
    [J]. CLINICAL BIOCHEMISTRY, 2020, 86 : 1 - 7
  • [20] Bailey JJ., 2021, ONTARIO COVID 19 SCI